Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: An evidence-based strategy to reduce the burden of late-developing diabetes complications

Diabetes and Metabolism

Volumn 30, Issue 6, 2004, Pages 509-516

  Consoli, A ^a   Gomis, R ^b   Halimi, S ^c   Home, P D ^d,h   Mehnert, H ^e   Strojek, K ^f   Van Gaal, L F ^g  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e Klinikum Schwabing   (Germany)

^f Dept Int Dis Diabetol/Nephrol ^*  (Poland)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Diabetic complications; Metformin; Oral glucose lowering therapy; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIOBESITY AGENT; GLIBENCLAMIDE; GLUCOSE; INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; DIET; EVIDENCE BASED MEDICINE; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; LACTIC ACIDOSIS; LIFESPAN; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; UNITED KINGDOM; WELLBEING;

EID: 11244253854     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70148-9     Document Type: Article

References (72)

1. Passa P. Diabetes trends in Europe. Diabetes Metab Res Rev 2002, 18, S3-S8.
2. Bagust A, Hopkinson PK, Maslove L, Currie CJ. The projected health care burden of type 2 diabetes in the UK from 2000 to 2060. Diabet Med 2002, 19,1-5.
3. Dunstan DW, Zimmer PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance. The Australian diabetes, obesity and lifestyle study. Diabetes Care 2002 25, 829-34.
4. st century Europe? Diabetes Care 2001, 24, 1377-83.
5. Rathmann W, Icks A, Haastert B, Giani G, Lowel H, Mielck A. Undiagnosed diabetes mellitus among patients with prior myocardial infarction. Z Kardiol 2002, 91, 620-5.
6. Taubert G, Winkelmann BR, Schleiffer T, et al. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J 2003, 145, 285-91.
7. Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting glycaemia: the current status of definition and intervention. Diabet Med 2002, 19, 708-23.
8. Colagiuri S, Hussain Z, Zimmet P, Cameron A, Shaw J. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care 2004, 27, 367-71.
9. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 2004, 27, 727-33.
10. Spijkerman AM, Yuyun MF, Griffin SJ, Dekker JM, Nijpels G, Wareham NJ. The performance of a risk score as a screening test for undiagnosed hyperglycemia in ethnic minority groups: data from the 1999 health survey for England. Diabetes Care 2004, 27, 116-22.
11. Buysschaert M, Vandenbroucke C, Barsoum S. A type 2 diabetes screening program by general practioners in a Belgian at risk population. Diabetes Metab 2001, 27, 109-14.
12. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003, 26, 725-31.
13. Uusitupa M, Lindi V, Louheranta A, et al. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 2003, 52, 2532-8.
14. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346, 393-403.
15. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344, 1343-50.
16. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20, 537-44.
17. Swinburn BA, Metcalf PA, Ley SJ. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care 2001, 24, 619-24.
18. American Diabetes Association. Prevention or delay of type 2 diabetes. Diabetes Care 2004, 27, S47-S54.
19. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999, 16, 715-30.
20. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14, 173-94.
21. Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg 2003, 58, 335-41.
22. Hanley AJ, McKeown-Eyssen G, Harris SB, et al. Cross-sectional and prospective associations between proinsulin and cardiovascular disease risk factors in a population experiencing rapid cultural transition. Diabetes Care 2001, 24, 1240-7.
23. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 2003, 26, 977-80.
24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352, 854-65.
25. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352, 837-53.
26. Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? Circulation 2002, 106, 2760-3.
27. UK Prospective Diabetes Study (UKPDS) Group. Qulaity of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999, 22, 1125-36.
28. Oxford University Diabetes Trials Unit. Preliminary information from 5 years of post-study monitoring in a subset of the UKPDS cohort is available at http://www.dtu.ox.ac (last accessed April 7 2004).
29. Fox CS, Sullivan L, D'Agostino RB Sr, Wilson PW. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care 2004, 27, 704-8.
30. Spijkerman AM, Dekker JM, Nijpels G, et al. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study. Eur J Clin Invest 2002, 32, 924-30.
31. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyhuride/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001, 24, 151-8.
32. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002, 25, 2244-8.
33. ADVANCE Study Group. Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. Diabetologia 2001, 44, 1118-20.
34. Prisant LM. Preventing type II diabetes mellitus. J Clin Pharmacol 2004, 44, 406-13.
35. Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002, 25, 1737-43.
36. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359, 2072-7.
37. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290, 486-94.
38. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27, 155-61.
39. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25, 10-6.
40. Burgers JS, Bailey JV, Klazinga NS, Van Der Bij AK, Grol R, Feder G. Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. Diabetes Care 2002, 25, 1933-9.
41. Treatment recommendations for type 2 diabetes. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) Diabetes Metab 1999; 25 Suppl 6:1-79.
42. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). Br Med J 2004 (in press).
43. Haffner SM, Lehto S, Rönnema T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339,229-34.
44. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000, 23, 1619-29.
45. McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PW, Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004, 27, 538-46.
46. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. Diabetes Care 1998, 21, 1686-90.
47. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003, 26, 3153-9.
48. McIntosh A, Hutchinson A, Home PD, et al. Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose. Sheffield: ScHARR, University of Sheffield, 2001. Also available at http://www.nice.org.uk.
49. Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev, 1995, 11(suppl. 1), S57-S62.
50. Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 1999, 22, 33-7.
51. Melchior WR, Jaber LA. Metformin: an antihyperglycemic agent for treatment of type II diabetes. Ann Pharmacother 1996, 30, 158-64.
52. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002, 25, 89-94.
53. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000, 23, 381-9.
54. Wei IN, Sung FC, Lin CC, Lin RS, Chiang CC, Chuang LM. National surveillance for type 2 diabetes mellitus in Taiwanese children. JAMA 2003, 290, 1345-50.
55. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Type 2 diabetes in Asian-Indian urban children. Diabetes Care 2003, 26, 1022-5.
56. Cockram CS. The epidemiology of diabetes mellitus in the Asia-Pacific region. Hong Kong Med J 2000, 6, 43-52.
57. Mehnert H, Sewering H, Reichstein W, Voigt H: Früherfassung von Diabetikern in München 1967/68. Dtsch Med Wschr 1968, 93, 2044-205.
58. Ehtisham S, Barrett TG, Shaw NJ. Type 2 diabetes mellitus in UK children-an emerging problem. Diabet Med 2000, 17, 867-71.
59. Kiess W, Bottner A, Raile K, et al. Type 2 diabetes mellitus in children and adolescents: a review from a European perspective. Horm Res 2003, 59, 77-84.
60. Turner RC, Cull CA, Frighi V, Holman RR. Glycaemic control with diet, sulphonylurea, metformin or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281, 2005-12.
61. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000, 321, 405-12.
62. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997, 103, 491-7.
63. Van Gaal L-F, Maislos M, Schernthaner G, Rybka J, Segal P. Miglitol combined with metformin improves glycaemic control in type 2 diabetes. Diabetes Obes Metab 2001, 3, 326-31.
64. Marre M, Van Gaal L, Usadel K, Ball M, Whatmough I, Guitard C. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomised trial with type 2 diabetes patients. Diabetes Obes Metab 2002, 4, 177-86.
65. Van Gaal L-F, De Leeuw I-H. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 2003, 46 (suppl. 1), 44-50.
66. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333, 541-9.
67. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance®) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002, 19, 673-80.
68. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001, 18, 828-34.
69. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002, 4, 201-8.
70. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets - results of a retrospective cohort study. Curr Med Res Opin 2004 (in press).
71. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2003, 2, CD002967.
72. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003, 163, 2594-602.